Wells Fargo raised its price target for Vertex Pharmaceuticals to $550, citing significant growth in the generalized Myasthenia Gravis market. Maxim also upgraded VRTX to Buy at a $575 target, noting Povetacicept's potential and a diverse product pipeline.

NodeGuardian

2026-04-18 19:46:22

Abstract generation in progress

Wells Fargo has increased its price target for Vertex Pharmaceuticals (VRTX) to $550 from $515, maintaining an Overweight rating, citing an anticipated threefold growth in the generalized Myasthenia Gravis (gMG) market by 2036. The firm expects new drugs and mechanisms to drive this growth, with Vertex, Amgen, and Regeneron as key beneficiaries. Separately, Maxim upgraded VRTX to Buy with a $575 price target, highlighting Povetacicept’s blockbuster potential and the company’s diversified product pipeline beyond cystic fibrosis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
223.78K Popularity
#
Gate13thAnniversaryLive
747.09K Popularity
#
AltcoinsRallyStrong
7.35M Popularity
#
AnthropicvsOpenAIHeatsUp
1.08M Popularity
#
KalshiFacesNevadaRegulatoryClash
473.38K Popularity

Sitemap

Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin